GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » 9-Day RSI

AVCNF (Avicanna) 9-Day RSI : 65.99 (As of Dec. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Avicanna 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-12-13), Avicanna's 9-Day RSI is 65.99.

The industry rank for Avicanna's 9-Day RSI or its related term are showing as below:

AVCNF's 9-Day RSI is ranked worse than
92.86% of 1093 companies
in the Drug Manufacturers industry
Industry Median: 49.74 vs AVCNF: 65.99

Competitive Comparison of Avicanna's 9-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avicanna's 9-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Avicanna's 9-Day RSI falls into.



Avicanna  (OTCPK:AVCNF) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avicanna  (OTCPK:AVCNF) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Avicanna 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Avicanna's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Avicanna Business Description

Traded in Other Exchanges
Address
480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Avicanna Headlines

From GuruFocus

Avicanna Announces Warrant and Debenture Repricing and Amendments

By GlobeNewswire GlobeNewswire 01-30-2023

Avicanna Announces Extension of Term Loan

By Value_Insider Value_Insider 10-31-2022

Avicanna Reports Q3 2024

By GlobeNewswire 11-14-2024

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

By GuruFocusNews GuruFocusNews 06-08-2022

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

By GuruFocusNews GuruFocusNews 07-08-2022

Avicanna Announces Changes of Auditors

By GlobeNewswire 08-02-2024

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

By GuruFocusNews GuruFocusNews 06-28-2022